Kiniksa Pharmaceuticals International (KNSA) Price to FCF (2018 - 2026)
Kiniksa Pharmaceuticals International's (KNSA) quarterly Price to FCF came in at 214.4 in Q2 2026, up 46.56% on a YoY basis from 146.29 in Q2 2025, and up 45.03% quarter-over-quarter from 147.83 in Q1 2026.
Powered by 
Analysis
Kiniksa Pharmaceuticals International (KNSA) Price to FCF (2018 - 2026) Analysis & Trends
Kiniksa Pharmaceuticals International (KNSA) has reported Price to FCF for 9 consecutive years, with 214.4 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Price to FCF rose 46.56% year-over-year to 214.4; the trailing twelve-month figure through Jun 2026 stood at 55.24 (down 10.53% YoY), and the FY2025 full-year result was 46.21, down 74.34% from the prior year.
- Price to FCF improved to 214.4 in Q2 2026 per KNSA's latest filing, from 147.83 in the prior quarter.
- Across five years, Price to FCF topped out at 4336.06 in Q1 2024 and bottomed at 1606.21 in Q3 2024.
- Historically, Price to FCF has averaged 224.4 across 5 years, with a median of 138.36 in 2025.
- The sharpest annual moves came in 2023 and 2024: Price to FCF tumbled 3625.64% in 2023, then jumped 487.86% in 2024.
- Over 5 years, Price to FCF stood at 176.42 in 2022, then jumped by 344.74% to 431.77 in 2023, then plunged by 59.03% to 176.89 in 2024, then dropped by 29.42% to 124.85 in 2025, then jumped by 71.72% to 214.4 in 2026.
- According to Business Quant data, Price to FCF over the past three periods registered 214.4, 147.83, and 124.85 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn |
| 10 | Kiniksa Pharmaceuticals International | 6.09 Bn | 5.56 Bn | 220.03 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 214.40 |
| Mar 31, 2026 | 147.83 |
| Dec 31, 2025 | 124.85 |
| Sep 30, 2025 | 175.53 |
| Jun 30, 2025 | 146.29 |
| Mar 31, 2025 | 132.85 |
| Dec 31, 2024 | 176.89 |
| Sep 30, 2024 | -1,606.21 |
| Jun 30, 2024 | 1,999.42 |
| Mar 31, 2024 | 4,336.06 |
| Dec 31, 2023 | 431.77 |
| Sep 30, 2023 | 143.86 |
| Jun 30, 2023 | -515.50 |
| Mar 31, 2023 | -1,505.03 |
| Dec 31, 2022 | -176.42 |
| Sep 30, 2022 | 28.77 |
| Jun 30, 2022 | -175.68 |
| Mar 31, 2022 | -40.40 |
| Dec 31, 2021 | -77.04 |
| Sep 30, 2021 | -53.58 |